Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

38.1%

8 terminated/withdrawn out of 21 trials

Success Rate

27.3%

-59.2% vs industry average

Late-Stage Pipeline

43%

9 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting7 withdrawn

Enrollment Performance

Analytics

Phase 2
9(47.4%)
Phase 3
8(42.1%)
Phase 4
1(5.3%)
Phase 1
1(5.3%)
19Total
Phase 2(9)
Phase 3(8)
Phase 4(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT05740943Phase 2Active Not Recruiting

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Role: collaborator

NCT06911606Phase 2Recruiting

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Role: collaborator

NCT06763666Phase 4Not Yet Recruiting

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Role: collaborator

NCT04680598Unknown

Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Role: collaborator

NCT03722498Phase 2Withdrawn

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Role: collaborator

NCT02973685Phase 3Completed

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Role: collaborator

NCT05476432Phase 3Recruiting

HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Role: collaborator

NCT03288805Active Not Recruiting

Cohort Study in South China

Role: collaborator

NCT04687163Phase 3Unknown

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Role: collaborator

NCT04667351Phase 3Unknown

HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial

Role: collaborator

NCT04044651Phase 2Withdrawn

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Role: collaborator

NCT02774187Phase 3Completed

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Role: collaborator

NCT03780634Phase 2Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Role: collaborator

NCT03803254Phase 2Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Role: collaborator

NCT03744247Phase 3Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Role: collaborator

NCT03782831Phase 2Withdrawn

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Role: collaborator

NCT03791918Phase 3Withdrawn

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Role: collaborator

NCT03812770Phase 2Unknown

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Role: collaborator

NCT02220088Phase 2Terminated

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Role: collaborator

NCT03468231Phase 3Unknown

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Role: collaborator